Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib in Glioblastoma
NCT02630030Phase 1Completed
- Sponsor
- Emory University
- Start
- Mar 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ixazomib in glioblastoma (GBM), sponsored by Emory University. Primary endpoints: Concentration of Ixazomib in Tumor Tissue at 3 hours and Concentration of Ixazomib in Blood and Plasma at 3 hours. Started Mar 2016; status: completed.
02
Drugs
ixazomib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02630030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02630030.